Literature DB >> 3685397

Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig.

D Ezra1, F R Laurindo, J F Czaja, F Snyder, R E Goldstein, G Feuerstein.   

Abstract

In previous studies we have shown that platelet-activating factor (PAF) is a potent vasoactive substance with deleterious effects on coronary blood flow (CBF) and myocardial performance. The present study further investigates the effects of PAF during its sustained intracoronary infusion in the blood-perfused domestic pig (n = 16). PAF infusion (1-9 nmol/min) produced triphasic changes in CBF (n = 7): an initial brief phase of coronary dilation (14 +/- 2% above baseline), followed by severe reduction in CBF due to increase in coronary vascular resistance and a third phase of escape that was characterized by return of CBF towards baseline in spite of continuing PAF infusion. In 9 remaining pigs PAF infusion had a biphasic response: the first phase of coronary dilation rapidly turned into severe coronary constriction accompanied by severe systemic hypotension and death within a few min. PAF infusion caused a profound rise in systemic arterial and coronary venous thromboxane B2 levels, while 6-keto-PGF1 alpha and leukotriene C4-immunoreactivity levels were not changed. Indomethacin completely blocked the rise in thromboxane level during PAF infusion and abolished the constrictor effect of PAF on the coronary vessels. These data suggest that PAF might play a detrimental role on the coronary circulation and cardiac function, primarily through thromboxane A2 mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3685397     DOI: 10.1016/0090-6980(87)90261-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  8 in total

1.  Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig.

Authors:  N A Flores; D J Sheridan
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Cardiovascular reactions and respiratory events during platelet activating factor-induced shock.

Authors:  S B Felix; G Baumann; P Raschke; C Maus; W E Berdel
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

3.  Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart.

Authors:  W M Hu; P C Choy; R Y Man
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

4.  Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart.

Authors:  W Hu; A A Kinnaird; R Y Man
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

5.  Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

Authors:  R Rabinovici; M D Sofronski; J F Renz; L M Hillegas; K M Esser; J Vernick; G Feuerstein
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

Review 6.  The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging.

Authors:  C Kroegel; C Kortsik; N Kroegel; H Matthys
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

7.  Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart.

Authors:  W M Hu; R Y Man
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 8.  Platelet-activating factor in cardiovascular stress situations.

Authors:  R Rabinovici; T L Yue; G Feuerstein
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.